<DOC>
	<DOCNO>NCT00000636</DOCNO>
	<brief_summary>To evaluate compare effectiveness 2-month regimen rifampin pyrazinamide versus 1-year course isoniazid ( INH ) prevent development tuberculosis patient coinfected HIV latent Mycobacterium tuberculosis ( MTb ) . Current guideline recommend 6 12 month treatment INH purify protein derivative ( PPD ) -positive individual . Problems treatment include compliance , adverse reaction , possibility prevent disease due INH-resistant organism . Studies suggest two three month rifampin pyrazinamide may effective long course INH . A two-month prevention course help increase compliance . In addition , use two drug ( rifampin pyrazinamide ) may help overcome problem drug resistance .</brief_summary>
	<brief_title>Prophylaxis Against Tuberculosis ( TB ) Patients With Human Immunodeficiency Virus ( HIV ) Infection Confirmed Latent Tuberculous Infection</brief_title>
	<detailed_description>Current guideline recommend 6 12 month treatment INH purify protein derivative ( PPD ) -positive individual . Problems treatment include compliance , adverse reaction , possibility prevent disease due INH-resistant organism . Studies suggest two three month rifampin pyrazinamide may effective long course INH . A two-month prevention course help increase compliance . In addition , use two drug ( rifampin pyrazinamide ) may help overcome problem drug resistance . After baseline screening , patient randomize one two treatment arm evaluate mean clinic visit monthly first three month , every three month first year ( additional clinic visit INH patient ) . Patients evaluate every six month . One group patient take INH plus vitamin B6 12 month . The group patient take 1 2 dos rifampin ( depend patient 's weight ) plus pyrazinamide 3-4 divide dose 60 day .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiretroviral treatment . Pneumocystis carinii pneumonia prophylaxis . Treatment acute opportunistic infection/malignancy . Aminoglycosides , quinolones fluoroquinolones ciprofloxacin ofloxacin &lt; 14 day treatment intercurrent infection . Patients must : HIV infection . Signed informed consent . Reasonably good health time study entry . Perceived life expectancy least six month . Allowed : Participation clinical trial long potential activity study drug Mycobacterium tuberculosis ( MTb ) , additive toxicity study agent , know possible drug interaction study drug . Prior Medication : Allowed : Treatment quinolones , fluoroquinolones , aminoglycosides , agent know potential activity M. tuberculosis . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Current active tuberculosis ( confirm suspect ) . Sensitivity intolerance study medication . Acute hepatitis . Evidence peripheral neuropathy , i.e. , sign symptom paresis , paresthesia , neuromotor abnormality , neurosensory deficit grade 3 worse . Inability concomitant medication change avoid serious interaction study drug . Concurrent Medication : Excluded : Quinolones , fluoroquinolones , aminoglycosides antituberculous activity ( may use 14 day treatment intercurrent infection ) .Other agent know potential antituberculous activity avoid , include follow : Aminosalicylic acid salt , capreomycin , clofazimine , cycloserine , ethambutol , ethionamide , isoniazid , kanamycin , pyrazinamide , rifabutin , rifampin , streptomycin , thiacetazone . Prior Medication : Excluded : History treatment &gt; 2 month agent know potential antituberculous activity specifically allow . Agents potential know antituberculous activity include follow : Aminoglycosides amikacin , aminosalicylic acid salt , capreomycin , ciprofloxacin , clofazimine , cycloserine , ethambutol , ethionamide , isoniazid , kanamycin , ofloxacin , pyrazinamide , quinolones fluoroquinolones , rifabutin , rifampin , streptomycin , thiacetazone . Patients may : Current active tuberculosis . Acute hepatitis . Peripheral neuropathy grade 3 grade 4 . Willing able , clinician 's opinion , comply treatment clinical management issue .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Isoniazid</keyword>
	<keyword>Pyrazinamide</keyword>
	<keyword>Pyridoxine</keyword>
	<keyword>Rifampin</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antitubercular Agents</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>